Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    19-March-2001      
Issue 78 Next Update - 14:00 UTC 08:00 EST    20-March-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Information On New Laser Heart Treatment Presented At ACC Conference

Patients Undergoing Procedure Experienced Relief From Severe Chest Pain

Eclipse Surgical Technologies, a medical device company specializing in cardiac angiogenesis, announced today that promising data from a randomized double-blinded independent assessment study of the company's minimally-invasive laser heart procedure, Percutaneous Transmyocardial Revascularization (PTMR), for treating advanced cardiovascular disease is being presented at the annual American College of Cardiology (ACC) conference in Orlando, Fla. March 18-21.

The BELIEF (Blinded Evaluation of Laser PTMR Intervention Electively For angina pectoris) study, conducted by Dr. Jan Erik Nordrehaug, who chairs the Department of Heart Disease at University Hospital of Bergen, Norway and is a member of the advisory committee of the Norwegian Ministry of Health, showed by independent assessment that patients who underwent the innovative catheter-based procedure were at least three times more likely to experience substantial relief from crippling chest pain called angina than those who received a sham procedure. The preliminary results of the randomized, double-blinded study measured and compared the reductions in chest pain between the two groups after six months.

Dr. Nordrehaug is attending the ACC conference and he presented the preliminary results from the BELIEF study yesterday, the first of three sessions focused on the study being presented during the conference.

"This is truly a pioneering study, carried out under strict scientific criteria," Dr. Nordrehaug said. "The BELIEF study using the Eclipse Axcis(TM) PTMR system was designed to isolate the 'placebo effect' component of functional benefit previously reported in PTMR and TMR publications. We were able to perform the PTMR procedure so that both the patient and physician were blinded as to whether or not laser energy was actually delivered."

Dr. Nordrehaug added that "the results of the BELIEF study convinced me that this procedure does indeed relieve angina and eliminates concern that 'placebo effect' is a primary source of persistent symptomatic relief. My patients treated with the laser showed significant improvement, which, I believe, is great news for the thousands of people around the world who suffer from this debilitating pain."

Dr. Nordrehaug presented his data at 2:45 p.m. Sunday, March 18. Highlights of his study will also be presented at 2:45 p.m. today, March 19 and at a breakfast meeting at 6:30 a.m. Wednesday, March 21 at the Embassy Suites International Drive Seminole Room.

In PTMR, which has not yet been cleared by the US Food and Drug Administration (FDA), a cardiologist positions an aligning catheter into the femoral artery and uses an Eclipse laser to create tiny channels in the heart muscle that are believed to stimulate the growth of new blood vessels (angiogenesis). PTMR is related to an FDA-cleared surgical procedure done with the Eclipse laser called TMR (Transmyocardial Revascularization).

The BELIEF study is the first double-blinded study of Eclipse's PTMR procedure. The Company had previously conducted a multi-center, prospective, randomized study that was the basis for the Company's PMA submission to the FDA in December 1999 seeking clearance to market PTMR.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.